EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of cholesterol‐lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink

Shahriar A Zamani iD, Barry I Graubard, Marianne Hyer iD, Emily Carver, Jessica L Petrick iD, Katherine A McGlynn iD

Cancer · 2024

DOI: 10.1002/cncr.35436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Shahriar A Zamani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Diabetes Mellitus, Type 2, Anticholesteremic Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although the relation between statin use and liver cancer risk has been extensively examined, few studies have examined other cholesterol‐lowering medications in relation to liver cancer risk. The authors examined five classes of nonstatin medications and liver cancer risk.

Methods

A nested case–control including 3719 cases and 14,876 matched controls was conducted within the Clinical Practice Research Datalink. Additional matches on type 2 diabetes and chronic liver disease were also implemented. The medications examined included cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin, and omega‐3 fatty acids. Conditional logistic regression estimated odds ratios and 95% confidence intervals.

Results

Cholesterol absorption inhibitor use was associated with reduced liver cancer risk in the overall analysis (odds ratio, 0.69; 95% confidence interval, 0.50–0.96) and in analyses based on type 2 diabetes and chronic liver disease status. Although bile acid sequestrant use was associated with increased liver cancer risk in the overall analysis (odds ratio, 5.31; 95% confidence interval, 3.53–7.97), the results of the analyses based on type 2 diabetes and chronic liver disease status were inconsistent. [Correction added on 19 August 2024, after first online publication: In the preceding sentence, the value ‘3.534’ has been changed to ‘3.54’.]. No associations were observed for the other medications.

Conclusions

Cholesterol absorption inhibitors may be associated with reduced liver cancer risk. Whether bile acid sequestrant use was associated with increased risk was only partially supported in the current study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsDiabetes Mellitus, Type 2Anticholesteremic AgentsHumansMaleFemaleMiddle AgedCase-Control StudiesAgedAdultRisk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorsFatty Acids, Omega-3

Stichwörter der Autor:innen

cholesterol‐lowering medicationsepidemiologylipid‐lowering agentsliver cancer

Substanzen

Anticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsFatty Acids, Omega-3

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
  • Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
  • Information Management Services, Rockville, Maryland, USA.
  • Slone Epidemiology Center, Boston University, Boston, Massachusetts, USA.

ORCID-Profile: Shahriar A Zamani, Marianne Hyer, Jessica L Petrick, Katherine A McGlynn

Förderung

  • Intramural NIH HHS
  • NIH HHS

Zitieren

APA

Zamani, S. A., Graubard, B. I., Hyer, M., Carver, E., Petrick, J. L., & McGlynn, K. A. (2024). Use of cholesterol‐lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink. Cancer. https://doi.org/10.1002/cncr.35436

Vancouver

Zamani SA, Graubard BI, Hyer M, Carver E, Petrick JL, McGlynn KA. Use of cholesterol‐lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink. Cancer. 2024. doi:10.1002/cncr.35436

BibTeX
@article{Zamani2024,
  author = {Zamani, Shahriar A and Graubard, Barry I and Hyer, Marianne and Carver, Emily and Petrick, Jessica L and McGlynn, Katherine A},
  title = {Use of cholesterol‐lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35436}
}
Kostenlos starten →